Skip to content

The role and mechanism of myokine fibroblast growth factor 21 and short-chain fatty acids in patients with chronic heart failure accompanied by depressive symptoms

The role and mechanism of myokine fibroblast growth factor 21 and short-chain fatty acids in patients with chronic heart failure accompanied by depressive symptoms

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029968
Enrollment
Unknown
Registered
2020-02-17
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

Case series:Nil

Sponsors

The First People's Hospital of Changzhou (The Third Affiliated Hospital of Soochow University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, regardless of gender; 2. The patients have the ability of expression and understanding, voluntarily fills in the informed consent file and cooperating with Blutabnahme; 3. The NYHA classificationis II ~ IV level; 4. Heart failure with reduced ejection fraction (HFrEF) was defined as left ventricular ejection fraction (LVEF) 40% and never been indicated LVEF 300pg/ml, patients with atrial fibrillation should > 600pg/ml; 6. Echocardiography on admission indicated the left atrium and/or left ventricle hypertrophy, or hospitalized for heart failure within 1 year. Depression is defined as a condition that is beyond the patient's tolerance or self-adjustment, having an impact on life and social functioning, but unreached the diagnostic criteria for psychosis.

Exclusion criteria

Exclusion criteria: 1. History of stroke or transient ischemic attack within 3 months; 2. Malignant tumor; 3. Patients with severe renal insufficiency: eGFR < 20 mL/min/1.73 m2 or patients requiring dialysis; 4. History of implantable cardiac resynchronization therapy (CRT); 5. Family history of psychosis, recent domestic calamity, or taking antidepressants and other antipsychotics; 6. Delirium, mental retardation, intubation, deaf-mute and other language communication disorders; 7. Obstructive sleep apnea syndrome; 8. History of substance abuse; 9. Have participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Psychological assessment;

Countries

China

Contacts

Public ContactLing Yang

The First People's Hospital of Changzhou (The Third Affiliated Hospital of Soochow University)

linda_yl@sina.com+86 13616110633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026